# Lifevantage Corp: overview LFVN · Nasdaq · CIK 849146 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lfvn.md) · [Financials](/companies/lfvn/financials.md) · [Filings](/companies/lfvn/filings.md) · [Insiders](/companies/lfvn/insiders.md) Latest reported revenue: [$42.4m](/filings/0001193125-26-371257.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-371257). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [47.2](/filings/0001628280-25-048792.md) | [67.8](/filings/0001628280-26-005428.md) | [58.4](/filings/0001193125-26-208922.md) | [55.1 d](/filings/0001193125-26-371257.md) | [47.6](/filings/0001628280-25-048792.md) | [48.9](/filings/0001628280-26-005428.md) | [43.7](/filings/0001193125-26-208922.md) | [42.4 d](/filings/0001193125-26-371257.md) | | Gross margin | % | [79.9%](/filings/0001628280-25-048792.md) | [80.5%](/filings/0001628280-26-005428.md) | [81.0%](/filings/0001193125-26-208922.md) | [79.9% d](/filings/0001193125-26-371257.md) | [79.5%](/filings/0001628280-25-048792.md) | [74.0%](/filings/0001628280-26-005428.md) | [79.0%](/filings/0001193125-26-208922.md) | [78.0% d](/filings/0001193125-26-371257.md) | | Operating margin | % | [5.4%](/filings/0001628280-25-048792.md) | [5.1%](/filings/0001628280-26-005428.md) | [6.9%](/filings/0001193125-26-208922.md) | [3.9% d](/filings/0001193125-26-371257.md) | [4.8%](/filings/0001628280-25-048792.md) | [1.0%](/filings/0001628280-26-005428.md) | [3.8%](/filings/0001193125-26-208922.md) | [3.9% d](/filings/0001193125-26-371257.md) | | Net margin | % | [3.9%](/filings/0001193125-26-208922.md) | [3.8%](/filings/0001193125-26-208922.md) | [5.9%](/filings/0001193125-26-208922.md) | [3.6% d](/filings/0001193125-26-371257.md) | [4.5%](/filings/0001193125-26-208922.md) | [0.6%](/filings/0001193125-26-208922.md) | [3.1%](/filings/0001193125-26-208922.md) | [3.0% d](/filings/0001193125-26-371257.md) | | Diluted EPS | $ per share | [0.14](/filings/0001628280-25-048792.md) | [0.19](/filings/0001628280-26-005428.md) | [0.26](/filings/0001193125-26-208922.md) | not reported | [0.17](/filings/0001628280-25-048792.md) | [0.02](/filings/0001628280-26-005428.md) | [0.11](/filings/0001193125-26-208922.md) | not reported | | Free cash flow | $m | [(0.9)](/filings/0001628280-25-048792.md) | [8.7 d](/filings/0001628280-26-005428.md) | [1.9 d](/filings/0001193125-26-208922.md) | [0.8 d](/filings/0001193125-26-371257.md) | [(2.7)](/filings/0001628280-25-048792.md) | [1.7 d](/filings/0001628280-26-005428.md) | [4.0 d](/filings/0001193125-26-208922.md) | [3.7 d](/filings/0001193125-26-371257.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [206](/filings/0000849146-23-000102.md) | [213](/filings/0000849146-24-000073.md) | [200](/filings/0000849146-25-000068.md) | [229](/filings/0001193125-26-371257.md) | [183](/filings/0001193125-26-371257.md) | | Gross margin | % | [81.5%](/filings/0000849146-23-000102.md) | [79.7%](/filings/0000849146-24-000073.md) | [79.3%](/filings/0000849146-25-000068.md) | [80.4%](/filings/0001193125-26-371257.md) | [77.6%](/filings/0001193125-26-371257.md) | | Operating margin | % | [3.7%](/filings/0000849146-23-000102.md) | [2.0%](/filings/0000849146-24-000073.md) | [2.2%](/filings/0000849146-25-000068.md) | [5.3%](/filings/0001193125-26-371257.md) | [3.3%](/filings/0001193125-26-371257.md) | | Net margin | % | [1.5%](/filings/0000849146-23-000102.md) | [1.2%](/filings/0000849146-24-000073.md) | [1.5%](/filings/0000849146-25-000068.md) | [4.3%](/filings/0001193125-26-371257.md) | [2.8%](/filings/0001193125-26-371257.md) | | Diluted EPS | $ per share | [0.24](/filings/0000849146-23-000102.md) | [0.20](/filings/0000849146-24-000073.md) | [0.23](/filings/0000849146-25-000068.md) | [0.75](/filings/0001193125-26-371257.md) | [0.40](/filings/0001193125-26-371257.md) | | Free cash flow | $m | [6.4](/filings/0000849146-23-000102.md) | [3.8](/filings/0000849146-24-000073.md) | [10.0](/filings/0000849146-25-000068.md) | [10.5](/filings/0001193125-26-371257.md) | [6.7](/filings/0001193125-26-371257.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lfvn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CAPITAL MANAGEMENT CORP /VA](/funds/1074273.md) | 2026-06-30 | $11.7m | 1,878,411 | | Reduced −563,508 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $4.2m | 669,418 | | Reduced −198,286 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.7m | 429,203 | | Reduced −219 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.7m | 268,605 | | Reduced −501,093 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $1.6m | 256,296 | | Reduced −19,900 | | [ENVESTNET ASSET MANAGEMENT INC](/funds/1407543.md) | 2026-06-30 | $1.4m | 229,907 | | Added +10,745 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.1m | 169,046 | | New +169,046 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $901.0k | 144,386 | | Added +39,722 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $861.5k | 138,056 | | New +138,056 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $754.3k | 120,830 | | Reduced −140,362 | ## Recent filings [All 1,034 filings](/companies/lfvn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 20:10 ET | [8-K](/filings/0001193125-26-414122.md) | 5.03 Amendment to articles or bylaws | 0001193125-26-414122 | | 2026-09-18 | 20:05 ET | [DEF 14A](/filings/0001193125-26-395513.md) | Proxy statement, period 2026-11-05 | 0001193125-26-395513 | | 2026-08-27 | 20:06 ET | [8-K](/filings/0001193125-26-371265.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-371265 | | 2026-08-27 | 20:05 ET | [10-K](/filings/0001193125-26-371257.md) | Annual report, period 2026-06-30 | 0001193125-26-371257 | | 2026-08-03 | 20:05 ET | [8-K](/filings/0001193125-26-330531.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-330531 | | 2026-05-06 | 20:06 ET | [8-K](/filings/0001193125-26-208934.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208934 | | 2026-05-06 | 20:05 ET | [10-Q](/filings/0001193125-26-208922.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208922 | | 2026-04-16 | 21:15 ET | [8-K](/filings/0001193125-26-159324.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-159324 | | 2026-02-04 | 21:06 ET | [8-K](/filings/0001628280-26-005431.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-005431 | | 2026-02-04 | 21:05 ET | [10-Q](/filings/0001628280-26-005428.md) | Quarterly report, period 2025-12-31 | 0001628280-26-005428 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001193125-26-371257.md), filed Aug 27, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/30182b9a-1ec8-4e49-bf07-1a5e2e4f2533) ## About the filer - CIK: 849146 - Tickers: LFVN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.